To update readers on the significant changes in infectious diseases pharmacotherapy.
Data Sources:
An Index Medians and Iowa Drug Information Service search (1993–1994) of English-language literature pertaining to the selected topic areas was performed. Additional information from abstracts presented at scientific meetings were identified by the authors.
Study Selection and Data Extraction:
All identified studies were screened and those judged relevant to the update were evaluated.
Data Synthesis:
New or clinically significant data since 1992 that related to peptic ulcer disease, microbial resistance (e.g., Enterococcus spp., Streptococcus pneumoniae, Mycobacterium tuberculosis, Candida albicans), immunomodulators, and AIDS were evaluated and compared with previous data.
Conclusions:
There have been several exciting and significant changes in infectious diseases pharmacotherapy evident from this review.
Get full access to this article
View all access options for this article.
References
1.
BatesRD, NahataMC. Once-daily administration of aminoglycosides. Ann Pharmacother1994;28:757-66.
2.
RotschaferJC, RybakMJ. Single daily dosing of aminoglycosides: a commentary. Ann Pharmacother1994;28:797-801.
3.
National Institutes of Health Consensus Development Conference Statement.Helicobacter pylori in peptic ulcer disease. JAMA1994;272:65-9.
4.
ParsonnetJ, HansenS, RodriguezL, GelbAB, WarnkeRA, JellumE,. Helicobacter pylori infections and gastric lymphoma. N Engl J Med1994;330:1267-71.
5.
HoskingSW, LingTKW, ChungSCS, YungMY, ChengAFB, SungJJY, etal. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomized controlled trial. Lancet1994;343:508-10.
6.
SchabergDR, CulverDL, GaynesRP. Major trends in the microbial etiology of nosocomial infection. Am J Med1991;91(suppl 3B):72S-5S.
7.
MoelleringRCJr.Emergence of enterococcus as a significant pathogen. Clin Infect Dis1992;14:1173-8.
8.
MoelleringRCJr.The enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic options. J Antimicrob Chemother1991;28:1-12.
9.
TailorSAN, BaileyEM, RybakMJ. Enterococcus, an emerging pathogen. Ann Pharmacother1993;27:1231-42.
10.
EliopoulosGM. Aminoglycoside resistant enterococcal endocarditis. Infect Dis Clin North Am1993;7:117-33.
11.
JonesRN, KehrbergE, ErwinME, SaderH.Epidemiologic studies of emerging antimicrobial resistance in USA hospitals: report from a forty medical center surveillance of parenteral susceptibility (abstract). Proceedings of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy.Orlando, FL, October 4–7, 1994:42C.
12.
Prudent vancomycin use.59Fed Reg 25761, May 17, 1994.
13.
CaputoGM, AppelbaumPC, LiuHH. Infections due to penicillin-resistant pneumococci. Arch Intern Med1993;153:1301-10.
14.
ChesneyPJ. The escalating problem of antimicrobial resistance in Streptococcus pneumoniae. Am J Dis Child1992;146:912-6.
Initial therapy for tuberculosis in the era of multidrug resistance.MMWR Morb Mortal Wkly Rep1993;42(RR-7):1-8.
19.
IsemanMD. Treatment of multidrug-resistant tuberculosis. N Engl J Med1993;329:784-91.
20.
PeloquinCA, BerningSE. Infection caused by Mycobacterium tuberculosis. Ann Pharmacother1994;28:72-84.
21.
HopewellPC. Impact of human immunodeficiency virus infection on the epidemiology, clinical features, management and control of tuberculosis. Clin Infect Dis1992;18:540-7.
22.
IsemanMD, CohnDL, SbarbaroJA. Directly observed treatment of tuberculosis. We can't afford not to try it. N Engl J Med1993;328:576-8.
23.
CohnDL, CatlinBJ, PetersonKL, JudsonHN, SbarbaroJA. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. Ann Intern Med1990;112:407-15.
24.
WeisSE, SlocumPC, BiaisFX, KingB, NunnM, MatneyGB,. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med1994;330:1179-84.
25.
BerningSE, HuittGA, IsemanMD, PeloquinCA. Malabsorption of anti-tuberculosis medications by a patient with AIDS (letter). N Engl J Med1992;327:1817-8.
26.
PeloquinCA, MacPheeAA, BerningSE. Malabsorption of antimycobacterial medications (letter). N Engl J Med1993;329:1122-3.
27.
GordonSM, HorsburghCR, PeloquinCA, HavlikJA, MetchockB, HeifetsL,. Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease. J Infect Dis1993;168:1559-62.
28.
PeloquinC, NittaA, BurmanW, BrudneyK, McGuinnessM, Miranda-MassariJ,. Incidence of low tuberculosis drug concentrations in AIDS patients (abstract). Proceedings of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, FL, October 4–7, 1994:M9.
29.
American Thoracic Society.Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Repir Crit Care Med1994;149:1359-74.
30.
National Nasocomial Infection Surveillance System.Nasocomial fungal infections in US hospitals 1980–1990 (abstract). Proceedings of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, GA, October 21, 1990:1129.
31.
MillonL, ManteauxA, Reboux G, DrobacheffC, MornodM, BaraleT,. Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype. J Clin Microbiol1994;32:1115-8.
32.
TroilletN, DurusselC, BilleJ, GlauserMP, ChaveJP. Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis1993;12:911-5.
33.
LuceJM. Introduction of new technology into critical care practice: a history of HA-1A human monoclonal antibody against endotoxin. Crit Care Med1993;21:1233-41.
34.
News release.Synergen stops clinical trial of Antril for severe sepsis. Boulder, CO: Synergen, July 18, 1994.
35.
FisherCJr, DhainutJFA, OpalSM, PribbleJP, BalkRA, SlotmanGJ,. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA1994;271:1836-43.
36.
WherryJ, WenzelR, Wunderink R, SilvermanH, PerlT, NasrawayS,. Monoclonal antibody to human tumor necrosis factor (TNF MAb): multi-center efficacy and safety study in patients with sepsis syndrome (abstract). Proceedings of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA, October 17–20, 1993:696.
37.
CarletJ, CohenJ, AnderssonJ, BihariD, KhainautJF, GardlundB,. INTERSEPT: an international efficacy and safety study of monoclonal antibody (MAB) to human tumor necrosis factor (hTNF) in patients (Pts) with the sepsis syndrome (abstract). Proceedings of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, FL, October 4–7, 1994:B1.
38.
SadoffJ.Soluble TNF receptors. Proceedings of the Third International Congress of the Immune Consequences of Trauma, Shock and Sepsis: Mechanisms and Therapeutic Approaches. Munich, Germany, March 5, 1994.
SandeMA, CarpenterCC, CobbsCG, HolmesKK, SanfordJP. Antiretroviral therapy for adult HIV-infected patients: recommendations from a state of the art conference. JAMA1993;270:2583-9.
41.
Concorde Coordinating Committee.Concorde: MRC/ANRS randomized double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet1994;343:871-81.
42.
VolberdingPA, LagakosSW, KochMA, PettinelliC, MyersM, BoothDK,. Zidovudine in asymptomatic human immunodeficiency virus infection. N Engl J Med1990;322:941-8.
43.
VolberdingPA, LagakosSW, GrimesJM, SteinDS, BalfourHH, ReichmanRC,. The duration of zidovudine benefit in persons with asymptomatic HIV infection. JAMA 1994;272:437-42.
44.
OsmondD, CharleboisE, Lang W, ShiboskiS, Moss A. Changes in AIDS survival time in two San Francisco cohorts of homosexual men, 1983 to 1993. JAMA 1994;271:1083-7.
45.
LundgrenJD, PhillipsAN, PedersonC, Clumeck N, GatellJM, JohnsonAM,. Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. JAMA 1994:271:1088-92.
46.
AbramsDI, GoldmanAI, LaunerC, KorvickJA, NeatonJD, CraneLR,. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. N Engl J Med 1994;330:657-62.
47.
DunkleLM, PaviaA, Messina M, CrossA, BMS-019 Study Group. Stavudine (d4T) vs zidovudine (ZDV) for the treatment of HIV-infected patients with CD4 counts of 50–500 cells/mm3 following at least 6 months of ZDV (abstract).Proceedings of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, FL, October 3, 1994.
48.
ConnorEM, SperlingRS, GelberR, Kiselev P, ScottG, O'Sullivan MJ, etal. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
49.
Recommendations for use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1994;43(RR-11):1-20.
